Estimation of an optimal chemotherapy utilisation rate for breast cancer: Setting an evidence-based benchmark for the best-quality cancer care

European Journal of Cancer

Volumn 46, Issue 4, 2010, Pages 703-712

  Ng, Weng ^a   Delaney, Geoff P ^a   Jacob, Susannah ^a   Barton, Michael B ^a  

^a LIVERPOOL HOSPITAL   (Australia)

Author keywords

Benchmark; Breast cancer; Chemotherapy utilisation; Evidence based; Quality care

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; DRUG INDICATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; STATISTICAL MODEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENCHMARKING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PATIENT PREFERENCE; SENSITIVITY AND SPECIFICITY;

EID: 76049093924     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.002     Document Type: Article

References (47)

1. Hewitt M. Simone J.National Cancer Policy Board, Institute of Medicine. Ensuring Quality Cancer Care (1999), National Academy Press, Washington, DC
2. Malin J.L., Schuster M.A., Kahn K.A., et al. Quality of breast cancer care: what do we know?. J Clin Oncol 20 (2002) 4381-4393
3. Verdecchia A., Francisci S., and Brenner H. Et al.Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8 (2007) 784-796
4. Bilimoria K.Y., Stewart A.K., Winchester D.P., et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15 (2008) 683-690
5. Malin J.L., Schneider E.C., Epstein E.M., et al. Results of the National Initiative for Cancer Care Quality: How can we improve the quality of cancer care in the United States?. J Clin Oncol 24 (2006) 626-634
6. Surveillance Epidemiology and End Results (SEER) Program. National Cancer Institute, DCCPS, Surveillance Research Program. SEER*RX antineoplastic drug database (version 1.1.1). Available at: http://www.seer.cancer.gov (release date Jan 1, 2006).
7. National Breast Cancer Centre. Clinical practice guidelines for the management of early breast cancer, 2nd ed. National Health and Medical Research Council, Commonwealth of Australia, 2001.
8. National Breast Cancer Centre. Clinical practice guidelines for the management and support of younger women with breast cancer, 1st edition. National Health and Medical Research Council, Commonwealth of Australia, 2004.
9. National Breast Cancer Centre. Clinical practice guidelines for the management of advanced breast cancer. National Health and Medical Research Council, Commonwealth of Australia, 2001.
10. National Breast Cancer Centre. Recommendations for use of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer. Available at: [accessed 24.04.07].
11. National Comprehensive Cancer Network. National practice guidelines in oncology: breast cancer, V2.2007. Available at: [accessed 24.04.07].
12. National Cancer Institute. PDQ cancer information summaries: treatment of breast cancer. Available at: [accessed 24.04.07].
13. BC Cancer Agency. Cancer management guidelines: breast cancer. Available at: [accessed 24.04.07].
14. Cancer Care Ontario Practice Guideline Initiative. The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer: a clinical practice guideline. Available at: [accessed 24.04.07].
15. Cancer Care Ontario Practice Guideline Initiative. The role of HER2/neu in systemic and radiation therapy for women with breast cancer: clinical practice guideline. Available at: [accessed 24.04.07].
16. Cancer Care Ontario Practice Guideline Initiative. Adjuvant systemic therapy for node-negative breast cancer: practice guideline report. Available at: [accessed 24.04.07].
17. Clinical Oncology Information Network (COIN). Guidelines on the non-surgical management of breast cancer. Available at: [accessed 24.04.07].
18. Scottish Intercollegiate Guidelines Network. Management of breast cancer in women: a national clinical guideline. Available at: [accessed 24.04.07].
19. Goldhirsch A., Coates A.S., Gelber R.D., et al. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17 (2006) 1772-1776
20. National Health and Medical Research Council. Guide to the development, implementation and evaluation of clinical practice guidelines. Canberra, 1998.
21. Delaney G., Jacob S., Featherstone C., et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104 (2005) 1129-1137
22. Buccheri G., Ferrigno D., and Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A (1996) 1135-1141
23. National Comprehensive Cancer Network. Clinical practice guidelines in oncology for head and neck cancers, V1, 2007. Available at: [accessed 24.04.07].
24. Centre for Epidemiology and Research. Report on adult health from the New South Wales population health survey. Sydney, NSW Department of Health, 2006.
25. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia (Cancer Series No.37). Canberra, 2007.
26. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
27. Simes R.J., and Coates A.S. Patient Preferences for Adjuvant Chemotherapy of Early Breast Cancer: How Much Benefit Is Needed?. J Natl Cancer Inst Monogr 30 (2001) 146-152
28. Duric V.M., and Stockler M.R. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile?. Lancet Oncol 2 (2001) 691-697
29. Duric V.M., Stockler M.R., Heritier S., et al. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?. Ann Oncol 16 (2005) 1786-1794
30. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer. J Clin Oncol 19 (2001) 980-991
31. TreeAge Pro [computer program], Release 1.0. Williastown (MA): TreeAge Software, Inc; 2007.
32. National Breast and Ovarian Cancer Centre. National Breast and Ovarian Cancer Centre and Royal College of Surgeons National Breast Cancer Audit Public Health Monitoring Series 2007 Data. Surry Hills, NSW, 2009.
33. Hill D, Jamrozik K, White V, et al. Surgical management of breast cancer in australia in 1995. National Breast Cancer Centre, National Health and Medical Research Council, 1999.
34. Ragnhammar P., Brorsson B., Nygren P., et al. A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol 40 (2001) 391-411
35. Cancer Care Ontario. Chemotherapy utilization proportion of cancer patients who received intravenous (IV) chemotherapy within 6 months following diagnosis by year (2001-2004) and type of cancer. Available at: [accessed 24.04.07].
36. Commission on Cancer, American College of Surgeons. National Cancer Database Benchmark Reports: treatment of breast cancer diagnosed in 2006. Available at: [accessed 24.04.07].
37. Northern and Yorkshire Cancer Registry and Information Service. Cancer in the 21st century NYCRIS statistical report 2000-2004, V2. Available at: [accessed 24.04.07].
38. Craft P.S., Zhang Y., Brogan J., et al. Implementing clinical practice guidelines: a community-based audit of breast cancer treatment. Australian Capital Territory and South Eastern New South Wales Breast Cancer Treatment Group. Med J Aust 172 (2006) 213-216
39. Guadagnoli E., Shapiro C.L., Weeks J.C., et al. The quality of care for treatment of early stage breast carcinoma: is it consistent with national guidelines?. Cancer 83 (1998) 302-309
40. Piccirillo J.F. Importance of comorbidity in head and neck cancer. Laryngoscope 110 (2000) 593-602
41. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 2001 (Cancer Series No.28). Canberra, 2004.
42. New South Wales Central Cancer Registry. Node-negative Breast Cancer Cases by Age Group. Available at: [accessed 24.04.07].
43. Adjuvant! Online (homepage on the Internet). Source of prognostic estimates Adjuvant! Breast Cancer Help Files (Breast Cancer Standard Version), 2006. Available at: [accessed 24.04.07].
44. Chia S.K., Speers C.H., Bryce C.J., et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 (2004) 1630-1637
45. Joensuu H., Isola J., Lundin M., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9 (2003) 923-930
46. Andrulis I.L., Bull S.B., Blackstein M.E., et al. Neu/erbB-2 Amplification Identifies a Poor-Prognosis Group of Women With Node-Negative Breast Cancer. J Clin Oncol 16 (1998) 1340-1349
47. Troung P.T., Lee J., Kader H.A., et al. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer 41 (2005) 1267-1277